In order to assess a possible connection between p53 and responsiveness to the small-molecule inhibitor YK-4-279, we analyzed a panel of different cancer cell lines (colon cancer, ES, melanoma) with known p53 wild-type (n = 5) or loss-of-function (n = 5) background. This evidence concerns the gene TP53 and malignant colon neoplasm.